Clinical Trials on Lymphoblastic Leukemia, Acute

Total 18663 results

St. Jude Children's Research Hospital
AbbVie

Active, not recruiting

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia

United States
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Queen Mary University of London
Gilead Sciences

Unknown

Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) (MARALL)

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

United Kingdom
University of Washington
National Cancer Institute (NCI)

Completed

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage

United States
medac GmbH
Syneos Health

Recruiting

PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia

Acute B-Cell Lymphoblastic Leukaemia

Brazil
Assistance Publique - Hôpitaux de Paris

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL)

Acute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic Leukemia

France
Chongqing Precision Biotech Co., Ltd

Recruiting

Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

China
Janssen Research & Development, LLC

Not yet recruiting

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Acute Leukemias

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...

Netherlands
Beijing GoBroad Hospital

Not yet recruiting

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
University of Pennsylvania

Active, not recruiting

CART22 Alone or in Combination With huCART19 for ALL

Refractory Acute Lymphoblastic Leukemia | Chemotherapy Resistant Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States, Canada, Australia, New Zealand, Switzerland
First Affiliated Hospital of Zhejiang University

Recruiting

Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL

Cytarabine+Thiotepa + Fludarabine + Busulfan | T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

China
National Cancer Institute (NCI)

Terminated

Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Secondary Acute Myeloid Leukemia | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Promyelocytic Leukemia (M3) | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia

United States
medac GmbH
Syneos Health; Celerion

Completed

Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukaemias (ALL) | Acute Myeloid Leukaemias (AML) | Juvenile Myelomonocytic Leukaemias (JMML)

Germany, United Kingdom, Italy, Austria, Czechia, Poland
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Ph-Like Acute Lymphoblastic Leukemia | Refractory Ph-Like Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Acute Lymphoblastic Leukemia in Remission

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | Philadelphia Chromosome, Ph^1^, Absent

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

Childhood Acute Lymphoblastic Leukemia | Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

United States
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
National Cancer Institute (NCI)
Children's Cancer Group

Completed

506U78 in Treating Patients With Refractory Hematologic Cancer

Recurrent Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Lymphoblastic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects

Childhood Acute Myeloid Leukemia in Remission | Cancer Survivor | Childhood Acute Lymphoblastic Leukemia in Remission | Cognitive Side Effects of Cancer Therapy

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Completed

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Shanghai Tong Ren Hospital
Gracell Biotechnology Ltd.

Unknown

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

B-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic Leukaemia

China
Ehab L Atallah

Recruiting

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

Acute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic Leukemia

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen BinDeBio Ltd.
Children's Hospital of Fudan University

Active, not recruiting

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Terminated

Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia
Shenzhen BinDeBio Ltd.
Xiangya Hospital of Central South University

Recruiting

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States, France, Spain, United Kingdom
St. Jude Children's Research Hospital
Pfizer

Terminated

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed Remission

United States
New York Medical College

Recruiting

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma (ALLO-T-DART)

T-cell Acute Lymphoblastic Leukemia | T-Cell Acute Lymphoblastic Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

Leukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic Leukemia

United States
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Therapeutic Advances in Childhood Leukemia Consortium
GlaxoSmithKline; Novartis

Terminated

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Relapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic Lymphoma

United States, France, Canada, Australia, Austria, Italy, Netherlands
Angiocrine Bioscience
California Institute for Regenerative Medicine (CIRM)

Completed

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia in Remission | Other Acute Leukemias

United States
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia

United States
Ehab L Atallah

Withdrawn

Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

Acute Lymphoblastic Leukemia in Complete Remission | Lymphoblastic Lymphoma in Complete Remission | Mixed Phenotype Acute Leukemia in Complete Remission

United States
St. Jude Children's Research Hospital

Recruiting

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Pediatric ALL | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Refractory

United States

Clinical Trials on Lymphoblastic Leukemia, Acute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations